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ABSTRACT 
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Apoptotic cell death is a crucial programmed mechanism for homeostasis of tissue. 
Mitochondrial apoptotic cell death is governed by BCL-2 protein family members. 
Aberrations in mitochondrial-mediated apoptosis lead to impaired cell death signaling in 
response to cellular damage and thereby promotes cancer cell survival. Upon with 
selectively interacting antiapoptotic BCL-2 proteins, BH3-only BCL-2 proteins play a 
crucial role in governing cellular damage. All anti-apoptotic members of the BCL-2 
protein family share a BH3 death domain, thus  BH3 profiling enables us to assess the 
apoptotic blocks caused by cancer cells. The myeloid cell leukemia-1 protein encoded by 
MCL-1 gene and is an anti-apoptotic member of a BCL-2 protein family. It is known as 
a survival molecule for the cancer cells and overexpression of it confers a resistance 
against chemotherapeutic drugs for the treatment of several types of cancer. These 
findings point out that the significance of the small molecule inhibitor for MCL-1. 
We have designed a small molecule inhibitor screening with the aid of the automated 
pipetting system, epMotion5070, through BH3 profiling method to monitor priming to 
cell death in the context of MCL-1 dependence.  We optimized the epMotion5070 by 
using a library, consisting of kinase inhibitors (80 molecules) for designing small 
molecule inhibitor screening. Then, we aimed to trigger mitochondrial apoptotic cell 
death via MCL-1 inhibitor molecules on non-small lung cancer cell lines ( H-23, H-1975) 
by screening a library (1280 molecules), which is accomplished by BH3 profiling. In this 
study, we identified specific small molecules for the inhibition of MCL-1. 
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ÖZET 
 
 
BH3 PROFİLLEME YÖNTEMİ İLE KÜÇÜK MOLEKÜL İNHİBİTOR TARAMA 
SİSTEMİNİN DİZAYN EDİLMESİ 
 
 
SEVDE NUR KARATAŞ 
Moleküler Biyoloji, Genetik ve Biyomühendislik, Yüksek Lisans Tezi, Temmuz 2018 
Tez danışmanı: Prof. Hüveyda Başağa 
 
 
Anahter kelimeler:miyeloid lösemi,apoptoz,mitokondri,BH3 profillemesi,BCL-2 protein 
ailesi 
 
 
Programlanmış hücre ölümü mekanimanızması hücre iç ortamında normal dengenin 
korunması için oldukça kritik bir mekanizma olarak bilinmektedir. Mitokondri aracılığı 
ile düzenlenen hücre ölümü mekanizması BCL-2 protein ailesi tarafından kontrol 
edilmektedir. Bu mekanizmada gerçekleşen anormallikler hücre ölümünü yöneten 
sinyallerlerde ciddi deformasyonlara sebep olmaktadır. Hücrenin zarar gördüğü 
durumlarda, mekanizmadaki deformasyon  kanser hücrelerinin hayatta kalmasını 
tetiklemektedir. Sadece BH3 bölgesine sahip BCL-2 proteinlerinin, mitokondriyal hücre 
ölümüne entegrasyonu antiapoptotic BCL-2 protein etkileşimi ile gerçekleşmektedir. 
Tüm anti-apoptotik proteinler BH3 bölgesine sahiptir ve bu yüzden BH3 profilleme 
yöntemi apoptotik proteinlerin bloklanmasını gözlemlemek için oldukça etkili bir 
yöntemdir. Miyeloid hücre lösemisi proteini MCL-1 geni tarafından kodlanır ve BCL-2 
ailesinin antiapoptotik bir üyesidir. MCL-1 kanser hücrelerinin sağ kalımı için önemli 
olup, daha çok üretilmesi, kanser hücrelerinde kemoterapik ilaçlara karşı direnç 
geliştirmektedir. Tüm bulgular MCL-1 proteininin hücre ölümünde yerinin önemli 
olduğunu belirtmektedir. Amacımız, BH3 profilleme metodu çerçevesinde, otomatik 
pipetleme yardımıyla küçük molekül inhibitörü tarama sistemidizayn ederek hücre ölümü 
cevabını/eğilimini indüklemektir. Bu amaç doğrultusunda, otomatik pipetleme cihazı 80 
molekülden oluşan kütüphane kullanılarak optimize edilmiştir. Ardından 1280 
molekülden oluşan kütüphane, BH3 profilleme yöntemi ile taranmıştır. MCL-1 proteinini 
inhibe edebilecek spesifik moleküller belirlenmiştir.  
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1. INTRODUCTION 
 
1.1. Apoptosis 
 
Apoptosis is an evolutionary preserved mechanism that allows facilitating tissue 
homeostasis and response to an external signal in metazoans 1. Due to the fact that the key 
role of apoptosis, either failure of the apoptotic machine or aberrant changes might be 
critical for the cell fate 2.  Chromatin condensation, nuclear fragmentation, breaking of 
cellular fragments and blebbing of the plasma membrane are included in the cellular 
hallmark of apoptosis 3. Caenorhabditis Elegans has been used to demonstrate the cell 
death mechanism. Previous studies showed that CED-3 and CED-4 trigger apoptosis in 
C. Elegans. CED-3, cysteine protease, is called caspase. Cysteinyl aspartate-specific 
proteases are responsible for activation of certain members of downstream target caspases 
4. Apoptosis is taking place through activation of initiator, inhibitor, and effector caspases. 
Effector caspases are existed as inactivate zymogens and cleavage of the certain substrates 
through caspases cause the formation of apoptotic body 2. 
Apoptotic pathways are operated by two molecular programs are known as an extrinsic 
and intrinsic pathway. The extrinsic pathway is guided by transmembrane receptors, Fas, 
and Tumor necrosis family. Death receptor signals stimulate death caspases 8 and 10, 
which are able to cleave death substrates 1. 
The extrinsic pathway is categorized into two pathways, based on the kind of signaling 
molecules and receptors. The extrinsic pathway is mediated by death receptors and these 
death receptors have specific ligands such as; Fas Ligand (FASL) or Tumor necrosis 
factor-related apoptosis-inducing ligand  (TRAIL) on the plasma membrane 4, 5. Binding 
of either FASL to FAS receptor or TRAIL to death receptor 4 and 5 leads to 
conformational change on their structure. The conformational change causes the 
formation of DISC complex 6.Upon engagement by FADD, self-cleavage of procaspase 
8 results in its activation. There are two main paths as consequences of activation of 
caspase 8. In type 1 cell, activation of caspase 8 allows activation of downstream effector 
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caspases, caspase 3 and caspase 7 that are responsible for activation of pro-death 
substrates, leading cellular changes characteristic of apoptosis 7, 8. Initiation of apoptosis 
is propagated by activation of mitochondrial pathway in the cell, which is called type 2 
cell. The signal from death receptors drives mitochondrial outer membrane 
permeabilization 9. Upon cleavage of pro-apoptotic BCL-2 member BID by caspase 8, 
translocated t-BID promotes mitochondrial membrane permeabilization to release 
cytochrome c 8. 
In contrast to the extrinsic pathway, the intrinsic pathway, which is induced by 
intracellular death signals, depends on mitochondrial depolarization and permeability 6. 
Mitochondrial outer membrane permeabilization (MOMP) triggers the releasing of 
apoptogenic factors, including cytochrome c, that begins caspase activation and thereby 
initiates apoptotic process 10. BCL-2 family proteins are responsible for the regulation of 
MOMP and thereby the cell fate is determined by the interaction between proapoptotic 
and antiapoptotic BCL-2 proteins. Cytochrome c engages with protein apoptotic protease 
activating factor 1 (APAF-1) and procaspase 9 and apoptosome complex is formed. By 
triggering caspase 3 and caspase 7, downstream caspases are activated. Therefore, the 
mitochondrial-mediated apoptotic process is committed 6. 
 
          Figure 1. 1 The two major pathways involved in apoptosis regulation. 
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1.1.1. BCL-2 Family Proteins 
BCL-2 family proteins play a crucial role on mitochondrial-mediated apoptotic pathway 
since members of BCL-2 family operate mitochondrial permeabilization and the release 
of several mitochondrial intermembrane space proteins into the cytosol. BCL-2 was 
identified as an oncogene in follicular lymphomas at the t(14;18) chromosomal breakpoint 
1. BCL-2 family proteins are classified as the multi-domain proapoptotic, the BH3 only 
proapoptotic and the multidomain pro-survival proteins. Although they belong to distinct 
groups, all BCL-2 family proteins share at least one BCL-2 homology domain (BH 1-4 
homology) 11. 
 
             Figure 1. 2 Two models for the activity of BH3 only proteins in apoptosis. 
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            Figure 1. 3 Selective binding among BCL-2 family proteins. 
1.1.2. Pro-apoptotic Proteins 
The pro-apoptotic proteins possess either multidomain or only BH3 domain. The effector 
proteins BAX and BAX, involves BH 1-3 domains, operates the commitment of 
mitochondrial cell death either directly or indirectly. Numerous proteins, that facilitate 
the activation state of BAX and BAK, are called activator proteins. BIM, BID, PUMA, 
and NOXA act as direct activators in case of BAX and BAK oligomerization, while BAD, 
NOXA and HRK which, indirectly induce apoptosis by exerting their function on 
antiapoptotic proteins, are called sensitizers 12. The activation of BAX and BAK act as a 
gate, leading a conformational change on the mitochondrial outer membrane and thereby 
operates MOMP. During permeabilization, intermembrane space proteins are released 
into the cytoplasm to induce apoptosis 10, 13. In addition to these proteins, BOK is 
described as a responsive element to ER stress 14. BH3 only proteins, including BIM, BID, 
BAD, BIK, NOXA, HRK, PUMA, which possess only BH3 death domain, transmit 
multiple cell death signals to mitochondria1.  
1.1.3. Pro-survival Proteins 
The pro-survival proteins, including BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1, and 
BCL-B, play a key role in the survival mechanism for the cancer cells. Cell type 
environment, activation level, and cell type are critical factors for cellular survival 
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mechanisms and the expression of pro-survival BCL-2 proteins relies on these factors 12. 
They block the core apoptotic mechanism by either precluding them from activating BAX 
or BAK or by binding effector proteins after their activation to expose BH3 domains 14. 
The BH3 domain, which is included in all BCL-2 family proteins, has an essential role 
for pro-death function. It is consisting of 20 amino acids amphipathic alpha-helix and only 
3 amino acid is evolutionary conserved 14. Structurally, BH1-3 regions are formed by 
helices 2, 3, 4 and 5. The conserved part of the BH3 domain mainly comprises 
hydrophobic cleft. The antiapoptotic proteins domains (BH1-4), including BH1, BH2, and 
BH3 constitute a hydrophobic groove that binds to the hydrophobic cleft of pro-apoptotic 
proteins 15. The crucial interaction begins at intracellular membranes and proceeds 
through mitochondrial outer membrane 11. 
 
Figure 1. 4 BH3 domain conservation among antiapoptotic BCL-2 family proteins.
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Figure 1. 5 BH3 domain conservation among BH3 only proapoptotic BCL-2 family 
proteins. 
 
1.2. Priming Classes in Apoptosis 
The cells might be influenced by chemotherapeutic agents in a different way according to 
the activation of some components in the apoptotic pathway. Priming can be described as 
a comparison mechanism depending on the tendency of committing the cell death, MOMP 
like a cliff and some cells are closer to the cliff comparing the others. Thereby, 
physiological features of these cells, that are defined as ‘’primed’’, are notably distinct 
from’’unprimed’’ cells since they tend to commit the cell death 16.  Priming feature 
basically facilitates the rate of mitochondrial outer membrane permeabilization. Several 
factors, including genetic background, perturbations in metabolism, might impact on 
priming levels of the cell 16. Priming levels are categorized into three distinct groups. The 
principle of BH3 Profiling relies on measuring apoptotic priming levels of the cell. 
 
 
7 
 
 
Types of Priming 
Class A cells are defined as competent although it is involved in the unprimed category. 
While activation of BIM and BID operates Class A priming, class A cells have no 
response to sensitizer peptides. Even though BAK and BAX oligomerization normally 
proceeds, they are not triggered by any pro-apoptotic proteins 17. 
Class B has some abnormalities in functions of BAX and BAK, and thereby it is defined 
as incompetent cells. Since the lack of BAK and BAX, there is no formation of the pore 
on their mitochondrial outer membrane. Therefore, it is not possible to release 
apoptogenic factors by mitochondria even if exposing high doses BIM and BID 17. 
In contrast to Class A, Class C primed cells have a response to not only activator but also 
sensitizer class peptides. In addition to pore formation by BAX and BAK, they might be 
activated by pro-death proteins. Class C primed cells are categorized by their response to 
the sensitizer peptides. While Class C MCL-1 is sensitive to BIM, BID, PUMA, BMF, 
and NOXA, it has no positive response to BAD and HRK.  BIM, BID, PUMA, BMF, and 
BAD are effective peptides to acquire a positive response to Class 2 BCL-2 proteins 17.  
 
Figure 1. 6 Apoptotic Priming. 
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1.3. Mitochondrial Outer Membrane Permeabilization (MOMP) 
 
Mitochondrial outer membrane permeabilization determines the cell fate and it is called 
a point of no return. In the absence of caspase activation, cells are still able to go through 
the apoptotic cell death 10. 
 
 
Figure 1. 7 Mitochondrial Outer Membrane Permeabilization through Bax/Bak     
Oligomerization. 
1.3.1. Caspase-Independent Cell Death 
There are several theories to demonstrate the molecular mechanism of caspase-
independent cell death. One of these models proposes that AIF and endonuclease G might 
have a contribution on caspase-independent cell death mechanism 10. Several 
perturbations in mitochondria might be described as a second model for caspase-
independent cell death. 
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1.3.2. Mitochondria-dependent Caspase Activation 
After mitochondrial outer membrane permeabilizes, a bunch of intermembrane space 
proteins are diffused from mitochondria. Binding of cytochrome c to APAF-1 leads to 
conformational change and activation of caspases. The following interaction between 
APAF-1 and procaspase-9 creates an apoptosome complex. Upon with activation of 
caspase 9 in apoptosome complex, caspase 3 and 7 trigger mitochondrial cell death. In 
the regulation of cell death, cytochrome c is an essential component to maintain the 
apoptotic process. However, other intermembrane space proteins, including Omi and 
Smac, have a key role in the apoptotic stimulation. Omi and Smac are responsible for 
induction of caspase activation through blocking of caspase inhibitors. Indeed, 
endonuclease G and AIF operates the DNA cleavage. In contrast to cytochrome c, the 
apoptotic process is able to maintain in the absence of Omi and Smac 10. It suggests that 
other IAPs are suppressed by another inhibitory molecules 18. 
 
1.4.BH3 Profiling 
 
The mitochondrial-mediated cell death has a crucial role on cell fate since the 
mitochondria might operate the response to several perturbations. To measure these 
changes in mitochondria at the molecular level, BH3 profiling, which has been developed 
by Letai Laboratory was introduced as a functional tool that utilizes either peptides or 
small molecules to trigger mitochondrial depolarization 19.  
 The BH3 profiling method is based on interactions between BCL-2 family and how these 
interactions impact the mitochondrial cell death. The BCL-2 family proteins facilitate 
mitochondrial outer membrane permeabilization which is called a point of no return. Due 
to the depolarization, caused by mitochondria, is a significant indicator to evaluate the 
response of the cell against chemotherapeutic agents, it is possible to predict the tendency 
of the cell for the mitochondrial apoptotic cell death, upon with measuring mitochondrial 
outer membrane permeabilization 19, 21. The principle of monitoring the changes in 
mitochondria is accomplished by the emission of fluorescent dye (JC-1). JC-1 is normally 
fluoresced green as a monomer while it fluoresces red in aggregation formation. It is able 
to accumulate in a matrix of mitochondria during polarization because of its lipophilic 
cation. While either BH3 peptides or small molecules are introduced as an input, 
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depolarization of outer membrane begins and results in releasing intracellular membrane 
space proteins and JC-1 dye. Thereby, upon measuring the red fluorescent, we are able to 
evaluate the potential of the outer membrane 22. Recently, there are five main types of 
BH3 profiling, including ELISA based profiling (enzyme-linked immune absorbance 
assay), plate-based assay via JC-1, JC1- FACS based assay, intercellular BH3 and 
Dynamic BH3. Distinctions between BH3 profiling methods enable to work with both 
heterogeneous and homogenous cell populations. Type of the population that needs to be 
analyzed, determines the choice of BH3 profiling method 20. 
1.4.1 Types of BH3 Profiling 
1.4.1.1. ELISA Based Profiling 
ELISA based BH3 Profiling is notably an efficient method to predict the amount of 
cytochrome c in mitochondria. After either BH3 peptides or small molecule exposure, the 
high amount of releasing cytochrome c from mitochondria points out that the cell is more 
primed since the proportion of cytochrome c is associated with priming. Even though the 
method is highly influential, detection of intermembrane space proteins requires 
antibodies and immunostaining methods 20. These requirements have some 
disadvantages, including low throughput, labor-intensive, expensive, and they do not 
allow real-time measurement 17. 
1.4.1.2. Whole Cell-Based BH3 Profiling Assay 
The whole cell-based BH3 profiling assay is designed to overcome the limitations of 
ELISA based method. Plate-based JC-1 BH3 profiling is the best-modified tool for cell 
lines and homogenous samples since it allows to get a bulk response instead of single cell 
measurement. Loss of membrane potential triggers releasing of cytochrome c from 
intermembrane space 17.  In order to measure the loss of mitochondrial membrane 
potential, the JC-1 fluorescent dye is used as a probe which has a dual emission. While 
JC-1 as a monomer fluoresces green, accumulation of JC-1 in the matrix forms JC-1 
aggregates and gives red fluorescent 17, 23. To exposure either BH3 peptides or small 
molecules into mitochondria, the plasma membrane permeabilization is required. 
Digitonin enables integration of BH3 peptides into mitochondria and causes 
permeabilization without disrupting membrane potential. During permeabilization, the 
mitochondrial stabilization is accomplished by the components of MEB Buffer. Upon 
with optimal concentration of digitonin, cell suspension are stained through JC-1 and 
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placed in 384 well plate. By integration of BH3 peptides, the second emission peak is 
detected at 590 nM and thereby diminishing in the red fluorescence is measured 17, 24. 
1.4.1.3. FACS based BH3 Profiling 
FACS based BH3 profiling is a novel method to aim to separate distinct populations in 
heterogeneous samples. This method offers a platform to detect mitochondrial response 
for a viable population. Single cells are tagged on cell surface markers, washed, 
permeabilized and exposed to BH3 peptides respectively. One of the critical points is 
considering the laser that excites the dye. In the manner of JC-1, 488 or 561 nm lasers are 
able to excite JC-1 dye. To analyze different populations, subpopulations need to be gated 
and profiled. The population of the profile is set between forwarding and side to scatter. 
Another critical point is setting the cytometer voltage 17. 
1.4.1.4. IBH3 Profiling Assay 
Intercellular BH3 profiling is a suitable method for heterogeneous cell population 16. 
Upon with formaldehyde, the fixation step provides to prevent peptide exposure. Fixation 
as distinct from plate-based BH3 profiling protects the cell structure and enables 
mitochondrial bound proteins to be stained. iBH3 profiling is designed for measuring 
retained JC-1 surroundings MOMP rather than fluorescent dye 20. Through cell surface 
markers, cells are stained with surface markers to distinguish cell populations. After the 
permeabilization step by digitonin, BH3 peptides are exposed at a certain concentration. 
Lastly, fixation is done by formaldehyde. Incubation with cytochrome c antibody allows 
the detection of retained cytochrome c. iBH3, which relies on a flow cytometer, allows 
the analysis of primary samples weeks after fixation 16. 
1.4.1.5. Dynamic Profiling Assay 
Pre-treatment with a drug to sample is introduced as a novel step in dynamic profiling 
assay in addition to the intercellular iBH3 method. The method proposes to display 
differences in priming states of the cells. To consider the chemotherapeutic response in 
vivo, dynamic BH3 profiling might act as biomarker 20.  It has been reported that DBP, 
when performed on breast cancer cell lines, could predict the response to chemotherapy 
25. 
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1.5.MCL-1 
 
MCL-1 belongs to the BCL-2 family protein, was revealed from human myeloid leukemia 
cell line. There is a sequence similarity between the carboxyl terminus of both MCL-1 
and BCL-2 and thereby it is a BCL-2 homolog gene. Even though numerous similarities 
exist including sequence, location and functional activity between MCL-1 and BCL-2, 
their expression levels are not equal at the same phase of differentiation. While expression 
of  MCL-1 rises, any considerable change is not observed in the expression of BCL-2 26. 
Although MCL-1 is largely located in mitochondria, nucleus, cytoplasm, and endoplasmic 
reticulum comprise low levels of anti-apoptotic MCL-1 28. The function of the MCL-1 
varies from localization to localization. While mitochondrial MCL-1 acts as a survival 
factor, a nuclear localization of  MCL-1 decelerates cell cycle 29.  It was identified that 
expression of  MCL-1 has a crucial role on postponement in cell death, in Chinese hamster 
ovary and hematopoietic cells. Since the deletion of MCL-1 gene declines the number of 
mature B cells as well as T cells, it is described as a critical factor for B and T cell 
development 26. 
There are some distinctions between MCL-1 and the other BCL-2 members. In contrast  
BCL-2 and BCL-xl, MCL-1 has only BH1, BH2 and BH3 domain and N-terminal 
extension, which comprises two PEST domains and phosphorylation sites. N-terminal of 
MCL-1 containing PEST domains regulates the protein stability of MCL-1, mitochondrial 
localization, and antiapoptotic activity 29.  MCL-1, which is regulated by transcriptional, 
posttranscriptional and proteasomal degradation, is distinguished from the others by 
having a short lifetime. Particularly, alternative splicing might reveal proapoptotic forms 
of MCL-1 at the post-transcriptional level 30, 31. Similar to the Bcl-2 protein family 
members besides from Bid and Bad, a transmembrane domain at the C terminus might 
support the interaction between MCL-1 and family members. It is estimated that the 
hydrophobic cleft, including BH1, BH2 and BH3 and transmembrane support anti-
apoptotic activity of MCL-1. 
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2. OBJECTIVE OF THE STUDY 
 
MCL-1 has been shown to be a major chemoresistance factor and survival in 
hepatocellular carcinoma 42, myeloid leukemia 43,44, lymphoblastic leukemia 45, multiple 
myeloma 46, and lung cancer 47. Due to the knocking out MCL-1 was corresponded with 
numerous side effects and disruption of some crucial roles including, B and T cell 
development, the best approach would be a targeting interaction of MCL-1 with 
proapoptotic BCL-2 proteins 48,49. Some clinical drugs including ABT 737 and ABT 263, 
have been developed to repress anti-apoptotic function of certain proteins such as; Bcl-
XL, Bcl-W, and BCL-2, whereas these drugs are not able to inhibit MCL-1. ABT 737 was 
the first molecule which targets BH3 binding groove of BCL-XL. It is decided that ABT-
737 is particularly effective for small cell lung cancer and lymphoma cells. However, due 
to the lack of oral viability of ABT-737, ABT 263 (navitoclax) was developed to 
compensate for the disadvantages of the ABT-737. ABT 263, which is analog of ABT-
737, contrıbuted to development of clinical studies for BCL-XL/BCL-2 inhibitors 37,38. S-
44563 was identified as a potential inhibitor of BCL-2/BCL-XL in uveal melanoma cells 
(MP41, MM26, and MM66) 33,39. In the context of MCL-1, BM-1197 is introduced as 
another inhibitor for blockage of BCL-2/BCL-XL in only MCL -/-  MEFs40. While ABT-
199 (Venetoclax), which is able to inhibit BCL-XL/BCL-2 in non-Hodgkin lymphoma 
(NHL), acute myeloid leukemia (AML), and ALL cell lines, utilization of either 
daunorubicin or cytarabine with Venetoclax triggers apoptosis in U937 and AML samples 
in the context of Venetoclax resistance 41. Even though these drugs have a potential to 
achieve inducing apoptosis in somehow, specific MCL-1 inhibition through protein-
protein interaction paves the way for clinical trials of inhibition of MCL-1. In early 
studies, ERK and lipoxygen inhibitors were introduced as a positive upstream molecule 
since ERK and lipoxygenase were the upstream element of MCL-1 in case of the acute 
ML-1 myeloblastic leukemia cell line and MiaPaCa-2 and APC-1 pancreatic cancer cells 
respectively 50,51.  
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Additionally, vascular endothelial growth factor (VEGH), which is a critical molecule for 
expression of MCL-1, was achieved by cyclin-dependent kinase inhibitor seliciclib in 
multiple myeloma 52. In the context of human endometrial and cervical cancer tissues and 
non-SCLC tissues, it was proved that activation of STAT3 is interrelated MCL-1 
overexpression. This finding points out that the significance of MCL-1 as a drug candidate 
to restore the apoptotic cell death mechanism in clinical studies for the treatment of cancer 
53,54. 
In the case of the MCL-1 inhibition through non-selective molecules would not be feasible 
and result in efficient consequences. Thereby, a novel and highly selective candidate 
MCL-1 inhibitors are reasonable to prevent such consequences 55. In BCL-2 protein 
family, NOXA selectively binds to MCL-1 to inhibit its apoptotic activity in CLL cells 
and human SCLC cells 55, 56, 57. Based on the MCL-1 NOXA interaction, celastrol proved 
that MCL-1 degradation with the aiding of NOXA in PC-3 human prostate cancer cell 
line 58. It is found that stabilized MCL-1 BH3 helix is selectively able to target MCL-1 in 
OMP2 multiple myeloma and Jurkat T cell leukemia cell lines 59. Another study revealed 
that MIM1 is a potential inhibitor to prevent the inhibition of BAK and BAX, caused by 
MCL-1 trigger caspases in MCL-1- rescued, BCR-ABL(p185)-transformed, Arf-null, 
MCL-1-deleted, B-lineage ALL (p185+ Arf−/− MCL-1del B-ALL) cells 60. All these 
studies emphasize that peptide derivatives, NOXA, may be utilized as an MCL-1 
inhibitor. 
The studies, based on NOXA-mediated targeting of MCL-1 claims that inhibitor GSI XII 
overcomes ABT-737 resistance in breast cancer cell lines 61.TW37, that is also an 
inhibitor of BCL-2 proteins, has a role in NOXA mediated inhibition of MCL-1 in H1299 
non-SCLC cell line 62. 
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Figure 2. 1 Selective inhibitor molecule for MCL inhibition. 
 
 
 
Drug Cell Line/tissue Concentration 
Celastrol-dependent 
NOXA upregulation 
and MCL-1 
degradation 
PC-3 human prostate cancer cell 
line 
1 μM-2 μM 
Stable MCL-1BH3helix  OPM2multiplemyeloma and 
Jurkat T-cell leukemia 
20 μ M-40 μ M 
MIM1 MCL-1 rescued p185+ Arf−/− 
MCL-1del B-ALL cells 
5 μM-20 μM 
Secretase inhibitor 
(GSIXII)  
BT549, MDAMB231, and MCF-7 
breast cancer cell lines 
10 μM 
TW-37  H1299 non-small cell lung cancer 
cell line 10 
10 μM 
Gossypol NB4leukemia cell line 2.5 μM-40 μM 
Compound 7 (PDBID: 
4WGI) N 
Not Available Not Available 
Table 2. 1 Non-selective inhibitors for MCL-1 (adapted from 63). 
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Drug Cell Line/tissue Concentration 
miR-101, miR-148, 
miR-153, miR-193a, 
miR518, miR-582, miR-
681, miR-876-3P, miR-
886-3P, miR-892b 
HCT-116 colon cancer cell line  
Transfection 
with 50nM 
 
 
miR-193b Malme-3 M, MeWo, SK-MEL-2, 
and SK-MEL-28melanoma cell 
lines 
 
Transfection 
with 5nM 
 
Compound 6h SMMC-7721human liver cancer 
cell line and MCF-7 human breast 
adenocarcinoma cell line 
10 μM 
Maritoclax K562, Raji, and multidrug-
resistant HL60/VCR cancer cell 
lines 
1 μM-2 μM 
 
Maritoclax HL60 acute myeloid leukemia cell 
line 
2 μM 
Maritoclax NCI-H460 human lung cancer cell 
line  
3 μM 
UMI-77 BxPC3 pancreatic cancer cell line 
 
4 μM 
A-1210477 NCI-H929myeloma cell line and 
NHL BCL2High cell lines 
3 μM-10 μM 
S-63845 Hematological cancer-derived cell 
lines, in vitro and in vivo acute 
myeloid leukemia models, solid 
tumor-derived cell lines and 
against tumor cells of mice 
10nM–
10Minvitro 
and 12.5–25 
mg/kg in vivo 
 
Table 2. 2 Selective inhibitor for MCL-1 (adapted from 63 ). 
Besides from NOXA mediated targeting and mimetics of NOXA, MCL-1 inhibiton was 
targeted via miRNAs. Numerous miRNAs are considered as potential molecules to induce 
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apoptosis by MCL-1 inhibition in HCT-116 colon cancer cell line. In the presence of 
ABT-263, MCL-1 mRNA and protein stability were raised and thereby, it was hard to 
degrade MCL-1. However, miRNA targeting overcame this problem in ABT-263 
treatment 64. It has been shown that mi-RNA 193  might be used for treatment in several 
melanoma cell lines to ABT -737 through binding of 3 UTR MCL-1 65. 
The structure-guided design approach plays a key role in the development of MCL-1 
inhibitor. S1(3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile) was 
described as a potent inhibitor to disrupt the interaction of MCL-1/BCL-2 with 
proapoptotic proteins 66. 
Maritoclax, isolated from Streptomycetes, was reported as a novel compound for the 
blockade of MCL-164. The distinction of Maritoclax from the others is a selective 
molecule for MCL-1 instead of BCL-2/BCL-XL in large granular lymphocyte leukemia. 
In the literature, there were some contradictory results. However, this molecule has a 
potential to be a novel molecule for MCL-1 inhibition 67. 
As another drug, UMI-77 has an inhibitory impact on MCL-1/BAX interaction by 
utilizing BH3 binding groove of MCL-1  in a BxPC3 pancreatic cancer cell line 68. 
Currently, A-1210477, derived from the indole-2 carboxylic acid core, was identified as 
a potent molecule to induce apoptosis and the concentration range is 3-10 uM in  NCI-
H929 myeloma cell line 69. 
Lastly, S63845 was considered as a most potent MCL-1 inhibitor at 10 nM to10 uM in 
hematological derived cancer cell lines and particularly AML models 63.  
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3. MATERIALS&METHODS 
 
3.1.Materials 
3.1.1. Chemicals 
Chemicals utilized in this thesis are given in Appendix A. 
3.1.2. Equipment 
Equipment utilized in this thesis is given in Appendix B. 
3.1.2.1. Multichannel Pipetting Robot ( EPMotion5070 ) 
Small molecule library (1280 molecules) was screened through pipetting robot 
(epMOtion5070-Eppendorf), which is already optimized for BH3 Profiling method. 
Because the number of small molecules that were screened is in thousands, epMotion 
was used to speed up the process by its automated system. 
      
       Figure 3. 1 Worktable (adapted from epMotion5070 manual). 
      A1 -50 ul Filter Tips                                                
      A2-96 PCR Well Plate 
      B1- Cells in MEB 1 X and Staining Solution 
      B2- 384 Costar Well Plate 
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Figure 3. 2 Reservoir Rack, reservoirs (30ml,100ml) and dispensing Tools (adapted 
from epMotion5070 manual).    
3.1.3. Solutions and Buffers 
Profiling Buffer (MEB Buffer 1X ) 
150mM Mannitol, 10mM HEPES, 50mM KCL, 5 mM Succinate Acid, 0.1% BSA  were 
dissolved in 100 ml ddH2O  for 250 ml MEB Buffer 1X. 0.02 mM EDTA and 0.02mM 
EGTA were added to the solution. The pH of the solution was adjusted to 7.5 +/-0.1 with 
KOH. DDH2O was added up to 250 ml.  The solution was filtered through 0.22-micron 
filter and stored at 4oC. 
3.1.4. Preparation of Staining Solution 
For 5 ml staining solution, 5 ul Oligomycin (20 mg/ml), 100 ul JC-1(100 uM), 10 ul 2 -
mercaptoethanol (5M), 4485 ul MEB Buffer 1X were respectively added into 15 ml falcon 
tube. Since the JC-1 is  light-sensitive, the solution should be stored in the dark. 
Oligomycin 
50 mg Oligomycin was dissolved in 1mL DMSO. The concentration of the stock solution 
was 20 mg/ml in DMSO. The solution was stored at -20oC. 
JC-1 Dye 
10mM JC-1 was dissolved in 1mL DMSO. The concentration of the stock solution was 
100uM/ml in DMSO. The solution was stored at -20oC.  
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FCCP 
10mM FCCP was dissolved in 1mL DMSO. The concentration of the stock solution was 
1mM/ml in DMSO. The solution was stored at -20oC. 
 2-Mercaptoethanol (BME) 
5 M 2-Beta-mercaptoethanol was diluted in ddH2O. 
3.1.5. Growth Media 
RPMI: RPMI 1640 growth medium supplemented with 10% heat-inactivated fetal bovine 
serum(FBS) and 1% Pen-Strep (100U/ml Penicillium and 100ug/ml Streptomycin. 
Freezing Medium: H-1975 and H-23 (non-small lung cancer cell lines were frozen in heat-
inactivated  FBS containing 20% sterile DMSO. 
3.1.6. Mammalian Cell Lines 
H-1975 (independent on MCL-1), H-23 ( dependent on MCL-1) non-small lung cancer 
cell lines were used to investigate the impacts of the MCL-1 inhibitors. 
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3.2.Methods 
 
3.2. 1.     Mammalian Cell Culture 
3.2.1.1. Maintenance of the cell lines  
H-23 and H-1975 were grown in sterile cell culture flask through RPMI 1640 and 
incubated at 37oC with 5% CO2. The cells were passaged (1:4 ratio) to a new cell culture 
flask at the confluence of 80 %. 
3.2.1.2. Cryopreservation of the cells  
In the freezing medium (80% FBS,20% DMSO), the cell was frozen for further use. 2-6 
x106 cells were counted and centrifuged at 300 G for 5 minutes. The supernatant was 
discarded, pelleted cells were resuspended in 1 ml freezing medium and transferred into 
labeled cryovial. The cryovials are stored in Mr. Frosty, which was found in -80 oC. In 
the next day, they were placed into a liquid nitrogen tank for a long-term storage. 
3.2.1.3. Thawing Mammalian Cells  
Cryovial was taken from the liquid nitrogen tank and thawed in a water bath (37oC). 9 ml 
RPMI 1640 was added into 15 ml falcon tube and frozen cells were gently transferred into 
15 ml falcon tube drop by drop. Cells were spanned down at 300 G for 5 minutes in order 
to remove DMSO. They were resuspended in RPMI1640 medium. Cells were placed into 
sterile tissue culture flask (T-25) and incubated at 37 oC with 5 % CO2. 
3.2.2.    BH3 Profiling Method 
BH3 Profiling method was performed by BH3 Profiling Plate-based protocol (Laboratory 
Manual by Jeremy Ryan). JC-1 plate based BH3 profiling was done and small molecule 
library LOPAC (1280 molecules) was used in this assay. Cells were resuspended in MEB 
Buffer (150 mM Mannitol, 10 mM HEPES – KOH pH 7.5, 50 mM KCL, 0.02 mM EGTA, 
0.02 mM EDTA, 0.1 % BSA, 5 mM Succinate). Small molecule inhibitors were 
permeabilized in staining solution (5 mM β-mercaptoethanol, 10 µg/ml Oligomycin, 1uM 
JC-1). Small molecule inhibitors in four different concentrations (10 uM, 1uM, 100 nM, 
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10nM) and cells were respectively transferred to 384 well plate. JC-1 fluorescence was 
analyzed at 545 nm excitation and 590 nm emission through Spectramax Gemini multi-
plate spectrofluorometer after 90 minutes incubation of small inhibitor molecules at 30 
oC17. 
The method, which is described above was used to optimize manual BH3 profiling 
protocol for the robot. Since the number of small molecules that we are going to screen is 
high, epMotion provide saving time by its automated system. Moreover, the pipetting 
robot enables to perform almost all steps of the screening including all liquid works from 
dilutions to the transfer of cells. Another point that we take advantage of is the precision 
of the experiments because there are 1280 small molecules that are going to be tested in 
different concentrations, in different cell lines with their replicates. At the same time, 
working volumes are considerably small. Additionally, the variations resulted from the 
unprecise manual transfer may affect the reliability of volume transfers. All these 
conditions indicate that providing the precision of the results is difficult when it is 
manually performed. However, the liquid transfer-robotic system provides a precision in 
an automated manner. 
3.2.2.1.  Optimization  
Dimethyl Sulfoxide, sample inhibitor library (80 molecules) and non-small lung cancer 
cell lines (H-23 and H-1975) were purchased from ATCC. Sample inhibitor library was 
diluted in DMSO and screening was performed by BH3 profiling method on those cell 
lines with the help of epMotion5070. 
3.2.2.2.  Preparation of Main Stocks through Serial Dilution of Small Molecules 
Small molecule library is composed of 80 small molecules in DMSO at 10 mM 
concentration and the volume of each small molecule is 25 ul. To dilute these inhibitors, 
DMSO was used as a solvent. It was purposed that each inhibitor must be dissolved in 
DMSO at 4 distinct concentrations (10uM, 1uM,100nM and 10 nM). Each small molecule 
was manually transferred to the first column of 96 PCR well plate for storage. 96 PCR 
well plate containing inhibitors was placed into labware B2. To transfer DMSO as a 
solvent, a reservoir rack, that involves a reservoir (30 ml), was located in labware B1. 25 
ml DMSO was manually added to the reservoir. 90 ul DMSO was added to other eight 
columns by pool command as an initial step of serial dilution. Then, 10 ul of each inhibitor 
was transferred into the second column, which contains 90 ul DMSO, with an aiding of 
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the multichannel epMotion pipette. After mixing each inhibitor with DMSO, 10 ul from 
each molecule was transferred to another column. This process was repeated for seven 
times without tip change since each 96 PCR well plate involves 16 distinct inhibitors at 
four different concentrations. As a result of the serial dilution, sources plates were 
prepared as main stocks for small molecules. 
 
Figure 3. 3 Serial Dilution and Transferring Inhibitors to the 96 well Experiment 
Plate. 
3.2.2.3. Transferring Inhibitors to the 96 well Experiment Plate 
The main stock plate and the experiment plate were placed in labware A2 and B2 
respectively. 12 ul of each small molecules were transferred from the main stock plate to 
the experiment plate through the reagent transfer command of epMotion. In each transfer 
step, the command for mixing was available before aspiration of the molecules and 50 ul 
filter tips were changed to prevent contamination. 
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Figure 3. 4 BH3 Profiling Method through epMotion 5070. 
3.2.2.4. BH3 Profiling Method through epMotion 5070 
BH3 Profiling method through epMotion was categorized in two basic steps. 
Transferring Staining Solution to Inhibitors 
50 µl filter tips were placed in labware A1. Reservoirs 1 and 2, including 4 ml staining 
solution and resuspend non-small lung cancer cells, were respectively placed in reservoir 
rack in the labware B1. 24 µl of staining solution was aspirated by a multichannel pipette 
of epMotion 5070 from reservoir 1 and dispensed to the experiment plate at A2, which 
have small molecule inhibitors. This procedure was repeated twice since the final volume 
of each small molecule must be 60 µl. In each transfer step, staining solution was 
dispensed from the top and thereby same 50 µl filter tips are utilized for each column of 
the 96 well PCR plate. 
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Transfering Inhibitors in Staining Solution from experiment plate to 384 Well Plate 
After addition of the staining solution to small molecule inhibitors in the previous step, 
the solution, consisting of small molecules and staining solution, was mixed three times 
at 15 ul mixing volume. Then, 15 µl solutions in each well were aspirated from the 
experiment plate and dispensed to the 384 well plate. The filter tips of the multichannel 
pipetting tool were changed for each column. 
Transfering Resuspend Cells to the 384 well plate 
Cells were detached from the surface of the cell culture flask (T-75). Then, they were 
centrifuged to remove trypsin at 300 G for 5 minutes. MEB 1X was used to wash the cells 
at 300 G for 5 minutes. Cells were resuspended in 4 ml MEB 1X and transferred into the 
reservoir. Before the aspiration of the resuspended cells, they were mixed three times at 
15µl mixing volume. 15 µl of resuspended cells were transferred into 384 well plate for 
each column. 
As a final step, DMSO and FCCP, which were negative and positive control respectively, 
were manually added into 384 well plate. Then 384 well plate was incubated at 30oC for 
90 minutes. 
3.2.2.5.  Procedures for Multichannel Pipetting Robot (EPMotion5070) 
Serial Dilution Command 
Dilution command operates the creation of dilution series. The reagent which needs to be 
diluted was transferred from well to well by the multichannel pipetting tool. First, the 
diluent was transported from the source to the destination plate and then dilution 
command was defined. Dilution command was consist of 3 stages with 1:10 dilution in 
each case. 
 
26 
 
 
          Source                                                         Destination                                              
Figure 3. 5  Serial Dilution 
Sample Transfer Command 
A sample is transferred from one position to another position.  
Reagent Transfer Command 
The reagent transfer command allowed a transfer from one labware as a source to 
numerous labware as a destination. To speed up the library screening, staining solution 
transfer was accomplished by the reagent transfer command. 16 distinct inhibitors at 4 
concentrations were able to be screened. 
                          
                        Source                                   Source 
                                            
Destination 
Figure 3. 6 Reagent Transfer Command 
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4. RESULTS 
 
4.1.Optimization Results 
Sample library screening was performed at the  Sabanci University Molecular Biology 
Genetics and Bioengineering Department, utilizing the Enzo (80 Molecules) for the 
optimization of pipetting robot (epMotion5070 - Eppendorf). We proposed to make sure 
the precision of the pipetting robot. Thereby, the same inhibitor was utilized with the same 
cell line H-23) and BH3 profiling assay was performed twice in four different 
concentrations. 
Non-small lung cancer cells were considerably primed in response to small kinase 
inhibitor molecule Apigenin. In the second repeat, the cell was primed as well as in the 
first repeat in the presence of Apigenin.  
In the presence of Y27632, H-23 cell line was primed like kinase inhibitors Apigenin. 
The percent of mitochondrial potential loss showed similarity in first and second 
measurements. In the context of Y-27632, the gap between the measurements was 
unexpectedly widen, the reason could be that the values of positive an negative controls 
were distinct from each other for each experiment. While the standard deviation was 
tolerable, consistency between the experimental repeats was preserved. 
According to our results, the experimental set up was succeeded by pipetting robot for the 
BH3 profiling methods due to both the first and second repeats seem consistent. 
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Figure 4. 1 BH3 profiles of non-small lung cancer cell lines (H-23, H-1975) in 
response to Triciribine, BML-259, H 89-2HCI and HA 1004 HCL for the 
optimization of pipetting robot. 
As we expected, each response showed the similarity as a percentage of mitochondrial 
potential loss and standard deviation seemed quite small for each inhibitor in response to 
Triciribine, HA 1004 HCI, and BML-259. 
Contrary to BML 259, Triciribine and, HA1004HCI, we found that H 89-2HCI  led to 
mitochondrial hyperpolarization. The coherence between the first and second 
measurements was preserved.         
4.2. Results for Actual Small Molecule Library Screening ( 1280 molecules) 
Mitochondrial apoptotic priming level determines the cell fate and facilitates the tendency 
of undergoing apoptosis 38. BH3 profiling method is a predictive approach to measure the 
changes in proapoptotic signaling 25. Several anti-apoptotic proteins play a crucial role on 
chemoresistance mechanism. Particularly, MCL-1 confers a resistance to either targeted 
therapy or chemotherapy. Thereby, we further investigated the mitochondrial cell death 
priming status of the cells through BH3 profiling in non-small lung cancer cell line panel. 
We screened 1280 small molecules through BH3 profiling with the aid of the automated 
pipetting system and obtained different profiles in the manner of mitochondrial membrane 
potential loss. DMSO and FFCP were used as negative and positive controls respectively. 
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While some drugs caused hyperpolarization, the others led to mitochondrial 
depolarization. Depolarization percentage was calculated by the formula’’ 1- ((Sample-
Positive Control (FCCP))/ (Negative Control-Depolarization))’’ for each inhibitor at four 
different concentrations. The variety of responses point out that BH3 profiling is an 
effective method for the screening of large numbers of molecules on cell lines. We 
performed a BH3 profiling method on H-23 cell line known to be Mcl-1 dependent. After 
selecting the candidate Mcl-1 inhibitors, we will use the H-1975 as a negative control cell 
line, known to be Mcl-1 independent. We showed that randomly selected results from our 
screen. 
  
 
Figure 4. 2 Dose-response curves of 44 distinct small molecules in non-small lung 
cancer cell line H-23 line at 90 minutes post-treatment. 
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We analyzed the depolarization percentage of each inhibitor using non-linear regression. 
Several small molecules depolarized the mitochondria and caused mitochondrial outer 
membrane potential loss. Each inhibitor was tested in four different concentrations. On 
the other hand, they led to mitochondrial depolarization besides from 3-
Aminopropionitrile fumarate salt, (+)2 Amino-5-phosphonopentanoic acid, 9 amino 
1,2,3,4 tetrahydroacridine hydrochlorides, Amifostine, KY-05009, which have distinct 
responses in different concentrations. 
 
 
    Figure 4. 3 Dose-response curves of 34 distinct small molecules in non-small lung   
cancer cell line H-23 line at 90 minutes post-treatment. 
 
31 
 
While non-small lung cancer cells (H-23) mostly have hyperpolarized membrane 
potential voltage, a few small molecules succeed in mitochondrial depolarization and 
caused membrane potential loss. In response to Carvedilol, Cirazoline hydrochloride and 
dequalinium chloride hydrate, primed cells (H-23) were having sufficient mitochondrial 
depolarization whereas some molecules led to very low or none mitochondrial 
depolarization in primed cells (H-23).  
 
Figure 4. 4 Dose-response curves of 47 distinct small molecules in non-small lung 
cancer cell line H-23 line at 90 minutes post treatment. 
Abiraterone acetate acid, Theophylline, Suramin hexasodium caused mitochondrial outer 
membrane potential loss at high concentrations (10µM, 1µM, 100nM), whereas 
mitochondrial hyperpolarization was observed at low concentration (10nM). However, 
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the other small molecules gave a positive result and led to mitochondrial depolarization 
at each distinct concentration. Even the depolarization rate was above 50 percent. 
Due to we obtained different responses in the context of mitochondrial outer membrane 
potential loss, we categorized these responses in five profiles. 
 
 
Figure 4. 5 BH3 profiles of non-small lung cancer cell line (H-23) in response to 
SML 1089 and F 3680. 
We categorized the molecules, which led high mitochondrial outer membrane potential 
loss in each concentration in profile 1. SML1089 and F 3680 caused mitochondrial 
depolarization since mitochondrial potential loss percent was high for each concentration 
in the bar chart. We found that these drugs might be specific molecules for the inhibition 
of MCL-1. Due to SML1089 caused more permeabilization of the mitochondrial outer 
membrane the mitochondrial cell membrane than F3680 at 10 nM, SML1089 would be a 
potent molecule for targeting of MCL-1. 
33 
 
 
Figure 4. 6 BH3 profiles of non-small lung cancer cell line ( H-23) in response to K 
1751, A 9501. 
We grouped small molecules that led to a mitochondrial hyperpolarization in profile 2. 
The mitochondrial potential loss was quite low in response to K1751 and A9501. It means 
that they caused mitochondrial hyperpolarization and that is why these drugs seem not be 
a specific molecule for the inhibition of MCL-1. In the lower part of figure 19, we showed 
the nonlinear regression analysis of  A9501 and K1751. While the hyperpolarization 
percent of A9501 was directly proportional to the concentration increase, H23 cell line 
had different responses at distinct concentrations in the presence of K1751. 
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Figure 4. 7 BH3 profiles of non-small lung cancer cell line ( H-23) in response to D 
7644 and K 1003. 
In the profile 3, we categorized the inhibitors that caused high mitochondrial potential 
loss only at a low dose (10 nM). H23 cell line was primed in response to D7644 and 
K1003 at only 10 nM concentration. K1003 seems a potent molecule rather than the 
D7644 because mitochondrial potential loss percent, which is caused by K1003, was more 
than the mitochondrial potential loss, caused by D7644. 
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Figure 4. 8 BH3 profiles of non-small lung cancer cell line ( H-23) in response to 
Q2128 and A9361. 
The other profile (P3) involves the small molecules which triggered mitochondrial 
depolarization only at high dose (10µM, 1µM,100 nM). In the response to Q2128 and 
A9361, the mitochondrial outer membrane of the cells was permeabilized. Even though 
we observed the mitochondrial depolarization in response to A9361 at high doses, 
depolarization percent was low compared to the Q2128. Moreover, the depolarization rate 
was directly proportional to the concentration increase in the presence of Q2128 only at 
high dose. Thereby, Q2128 seems more potent small molecule for MCL-1 inhibition. 
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Figure 4. 9 BH3 profiles of non-small lung cancer cell line ( H-23) in response to 
A3940 and O3011. 
In profile 5, even though the molecules led to mitochondrial depolarization, there was no 
direct proportion to the concentration due to the increase in concentration. To comment 
on this profile in detail, first we need to utilize these inhibitors on the H1975 cell line. If 
we observe the mitochondrial depolarization, we might perform cell death assays as 
further studies. 
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To sum up, we have counted the small molecule inhibitors and categorized these five 
distinct profiles into three basic groups, including depolarization, hyperpolarization and 
non-exclusive responses. We summarized the percentage of each group in the pie chart. 
 
 
 
Figure 4. 10 The percentage of each group in the small molecule inhibitor library.  
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4.3. EC50 Values 
  
The EC50 values of the molecules were determined by nonlinear regression analysis. 
The Name of the Inhibitor EC50 
Acetyl-beta-methylcholine chloride 82.71 
3'-Azido-3'-deoxythymidine- 1119 
GABA 148.2 
10058-F4 ~ 162449 
1-Aminobenzo triazole 62.2 
9-Amino-1-2-3-4-tetrahydroacridine 
hydrochloride 531 
KY-05009 ~ 6.517e+007 
Gabaculine hydrochloride ~ 0.004333 
YM 976 66.26 
UNC0379 trifluoroacetate salt 444.5 
R-(-)-Apomorphine hydrochloride 
hemihydrate 354.6 
Carboxymethyl hydroxylamine hemiHCl 379.4 
5-(NN-Dimethyl) amiloride 
hydrochloride- 3977 
Azathioprine 23.18 
Acyclovir 0.00015 
Rivastigmine tartrate 163.7 
Sandoz -035 179.8 
±)-2-Amino-3-phosphono-propionic acid ~ 7.347e+007 
L-Arginine 2 0.00003378 
Ezatiostat 159.9 
L-732 479.6 
Acetylsalicylic acid 4.6 
Aconitine 1.581 
-Acetylthiocholine chloride 72.57 
TNP ~ 4.161e+007 
-2-(2-Aminoethyl) isothiourea diHBr ~ 9.914e+006 
4-Amino benzamidine diHCI 0.0000339 
3-Aminopropionitrile fumarate salt 0.00003796 
Acetazolamide ~ 0.006471 
Amifostine 0.00006785 
Aminoguanidine hemisulfate 16.47 
Agmatine Sulfate 3909 
Arbidol hydrochloride 78.21 
Kyotorphin acetate salt- 904.3 
Arecoline hydrobromide 311.6 
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SirReal2 ~ 1.693e+007 
Atropine methyl bromide 1326000000 
Indinavir sulfate salt hydrate 230.3 
 
The Name of the Inhibitor EC50 Values 
N-Acetyl procainamide HCl- 5593 
Tienilic Acid 183.3 
Actinonin ~ 4.032e+008 
2-Chloro-2-deoxy-D-glucose ~ 7.073e+006 
CNQX disodium ~ 0.004335 
23-CX 546 482.5 
Cirazoline hydrochloride ~ 6.086e+006 
Tocainide hydrochloride 158.3 
Cirazoline hydrochloride ~ 6.086e+006 
P4-Di(adenosine- 5')tetraphosphate 
ammonium ~ 2.441e+006 
Decamethonium dibromide 0.00005588 
Dihydroouabain ~ 1.379e+007 
DNQX 83270000 
Dihydrokainic acid 9592 
WB-4101 hydrochloride ~ 502298 
NNGH 30840 
1=4-Dideoxy-1 4-imino-D-arabinitol ~ 2.111e+007 
SBI-0087702 2190 
2'3'-didehydro-3'- deoxythymidine 2069 
Debrisoquin sulfate 0.00003632 
SANT-1 1.675 
5-6- Dichlorobenzimida zole riboside 6.479 
L-3-4-Dihydroxy phenylalanine methyl 
ester hydrochloride ~ 1.937e+007 
2-3-Butanedione 38552 
NNN'N'-Tetramethylazodicarboxamide ~ 8.595e+009 
Dihydro ergotamine methanesulfonate 2062 
Carvedilol ~ 3.633e+006 
Diltiazem hydrochloride 0.00003305 
Diphenhydramine hydrochloride ~ 1.856e+007 
Diphenylene iodonium chloride ~ 4.421e-006 
Dequalinium chloride hydrate 31.02 
S)-3=5-Dihydroxyphenyl glycine 609.6 
Chlorcyclizine 49.83 
SR 59230A Oxalate salt 81.62 
rac BHFF 3481 
Zofenopril calcium 0.00001448 
SIB 1893 1874 
SIB 1757 ~ 7.796e+007 
Ketanserin tartrate 4018000000 
Danshensu sodium salt 7163 
1-(2-Methoxyphenyl) piperazine HCl 20.57 
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The Name of the Inhibitor EC50 
PAPP ~ 0.06996 
Dolasetron mesylate hydrate 196.9 
SR-95531 ~ 1.943e+006 
(±)-6-Chloro-PB hydrobromide 81.14 
L--threo-benzyl-aspartate ~ 0.004506 
Suramin hexasodium 2866 
SQ 22536 ~ 1.171 
Sepiapterin 18.57 
Amisulpride ~ 4.764e-006 
(±)-SKF 38393- N-allyl- ~ 9.584e-006 
SDZ-205-557 hydrochloride 307.7 
SB 206553 hydrochloride ~ 0.007837 
Granisetron hydrochloride 4.163 
L-Tryptophan ~ 0.001471 
Tranilast 57.42 
FAUC 213 ~ 0.008860 
Tolbutamide ~ 0.006004 
Tiapride hydrochloride 1794 
TCPOBOP ~ 1.207e+006 
Tetraisopropyl pyrophosphor amide 56.91 
Tetramisole hydrochloride 57.42 
Tetraethylthiuram disulfide ~ 1.813e+007 
DL-Trihexyphenidyl hydrochloride 2263 
Theophylline ~ 3.389e+007 
(E)-4-amino-2-butenoic acid ~ 7.033e+007 
Tetradecyl thioacetic 1675 
Abiraterone acetate acid ~ 7.068e+007 
Tyrphostin AG 879 ~ 5.712e+006 
Tetraethyl ammonium chloride 4776 
Terbutaline hemisulfate 31.11 
Triflupromazine hydrochloride ~ 0.004672 
Trimipramine Maleate salt ~ 0.007004 
Oltipraz metabolite M2 499.4 
TTNPB 1860000000 
Lubeluzole dihydrochloride 1204 
Triamterene ~ 0.009184 
Estetrol 1285 
Tetrahydrozoline hydrochloride 830.4 
N-p-Tosyl-L-phenylalanine chloromethyl 
ketone ~ 0.004617 
(6R)- 5- 6 7 8Tetrahydro-L-biopterin 
dihydrochloride ~ 5.898e-006 
cDPCP 14.3 
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The Name of the Inhibitor EC50 
Theobromine ~ 2.158e+007 
(±)-Taxifolin ~ 5.561e+007 
CYM-5520 39288 
Nedocromil 116 
Entecavir ~ 1.612e+010 
Pivmecillinam ~ 0.004345 
RU-SKI 43 maleate ~ 0.004345 
DL-Thiorphan ~ 2.091e+007 
(+-)-alpha-Lipoic Acid 1190 
Tulobuterol hydrochloride 1.296 
Trazodone hydrochloride 37.69 
BAY 61-3606 hydrochloride hydrate ~ 0.007705 
Triamcinolone 265.9 
S(-)-Timolol maleate 9125 
Triprolidine hydrochloride 173.5 
Tyrphostin AG 112 681 
Tyrphostin 1 898.5 
Tyrphostin 23 2438 
Na-p-Tosyl-L-lysine chloromethyl ketone 
HCl 381.7 
Pifithrin-µ 424.3 
Enclomiphenehydrochloride 290.5 
1-3-Dipropyl-8-p-sulfophenyl xanthine 201.8 
Gardiquimod ~ 0.004281 
VU0420373 49.95 
Amoxapine 246.1 
Aurora-A Inhibitor I 2097000000 
Arecaidine propargyl ester hydrobromide 8.036 
Aminobenztropine ~ 7.754e+006 
S(-)-Atenolol ~ 0.009875 
Table 4. 1 EC 50 values of randomly selected screening results. 
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5. DISCUSSION 
 
Cancer cells are governed by apoptotic inhibitions and proliferative signals. The 
mitochondrial apoptotic pathway relies on mitochondrial outer membrane 
permeabilization that is driven by interactions between BCL-2 family proteins. This 
family has a dual role in cellular homeostatic activities. BCL-2 family proteins provide 
the elimination of damaged cell from organism under hemostatic conditions whereas, in 
the case of cancer, their overexpression induces tumor development, chemoresistance, 
and metastasis. The network between BCL-2 family proteins decides how mitochondrial 
outer membrane permeabilization proceed. Once the abundance of pro-apoptotic proteins 
exceeds the binding capacity of antiapoptotic, the cell fate is determined as a suicide. 
Even though BCL-2 proteins are categorized into three groups, all of them possess BH3 
death domain 10, 18. BH3 profiling assay was used to determine the chemosensitivity of 
cancer cells and predict the ability of small molecules to trigger mitochondrial 
depolarization 17, 20. Since the BH3 domain of antiapoptotic proteins has a hydrophobic 
groove and its groove is deeper than pro-apoptotic proteins, targeting protein-protein 
interaction is a feasible approach for this study. We proposed finding a selective small 
molecule to inhibit MCL-1 through BH3 profiling method with the aid of automated 
system 10, 18. To adapt the manual BH3 profiling to pipetting robot, we designed an 
optimization protocol through the commands of the pipetting robot. We performed the 
optimization protocol through a sample molecule inhibitor library which is consist of 80 
kinase inhibitors. The effect of each inhibitor was tested twice to make sure the precision 
of the pipetting robot and critical points at each step of the method were properly 
considered.  
After the optimization step, we screened actual small molecule library (1280 molecules) 
at four different concentrations through BH3 profiling method with the aid of pipetting 
robot and investigated the ability of distinct inhibitors in the context of mitochondrial 
outer membrane permeabilization. BH3 profiling results have shown that a variety of the 
inhibitors result in distinct responses. While most of the molecules caused mitochondrial 
hyperpolarization, the others succeed in depolarizing mitochondria. To predict the 
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optimal concentration range of the candidate molecule, the inhibitors were utilized at four 
different concentrations (10 µM,1 µM,100 nM,10 nM). While the percent of 
mitochondrial outer membrane potential loss was high at 10 µM,1 µM and 100 nM 
concentrations in response to abiraterone acetate acid, theophylline, Suramin hexasodium, 
the response was declined at 10nM. However, there were some inhibitors that have a 
potential to depolarize the mitochondria at low concentrations rather than the high 
concentrations. To confirm the ability of the candidate molecules for mitochondrial 
depolarization, we are going to repeat the experiment three times. The negative control 
cell line (H-1975) will be utilized to makes sure whether the candidate molecules are 
potentially MCL-1 specific or not. If the candidate molecules lead to hyperpolarization of 
mitochondria, it means that the candidates would be notably MCL-1 specific molecules. 
Our initial results indicate that BH3 profiling assay is a functional method to provoke a 
response from mitochondria against chemotherapeutic molecules. Our results point out 
that the potential of utilizing BH3 Profiling method as a unique precision tool in medicine. 
In summary, we targeted pro-survival protein MCL-1 because it is known as a survival 
and chemoresistance factor. We screened 1280 small molecule inhibitors to find a specific 
small molecule for the inhibition of MCL-1. We categorized our results in five profiles. 
We are planning to perform a BH3 profiling assay through the candidate molecules, 
leading to mitochondrial depolarization, on H-1975 cell line. In order to confirm the 
specificity of the candidate small molecules to MCL-1, we need to apply the inhibitors 
our negative control cell line (H-1975), which is known as an MCL-1 independent. 
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7. APPENDICES 
 
APPENDIX A-Chemicals 
 
Chemicals and Media Components                                       Supplier Company 
Mannitol                                                                                    Sigma            
EDTA                                                                                        Sigma   
EGTA                                                                                        Sigma 
Succinic Acid                                                                            Sigma          
BSA (IgG Free)                                                                        VWR 
HEPES                                                                                      VWR 
Potassium chloride                                                                    Sigma 
Potassium hydroxide                                                                 Sigma 
Digitonin                                                                                   Sigma 
FCCP                                                                                        Sigma 
Oligomycin                                                                               Sigma 
JC-1                                                                                          VWR 
Trypan blue solution                                                                Thermofisher Scientific                                                                                                     
pH 4.0 buffer solution                                                              Merck Millipore 
pH 7.0 buffer solution                                                              Merck Millipore 
RPMI 1640                                                                               Gibco 
Trypsin                                                                                     Pantech                                                   
Ethanol                                                                                     Sigma 
Fetal Bovine Serum                                                                  Pantech 
DMSO                                                                                      Sigma 
Distilled Water                                                                         Merck Millipore 
2-Mercaptoethanol                                                                   Sigma 
Hydrocholoric acid                                                                  Sigma 
PBS                                                                                          Pantech 
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APPENDIX B-Equipment 
 
Equipment                                                                            Supplier Company 
Automated Cell Counter                                                         EVE 
Autoclave                                                                               HiClave HV-110, Hirayama, 
Isolab,  
Centrifuge                                                                               5418R, Eppendorf 
                                                                                                5702, Eppendorf 
                                                                                                5415R, Eppendorf 
                                                                                                Allegra X-15R, Beckman  
Balance                                                                                    Eppendorf 
CO2  Incubator                                                                         Binder 
Deep Freeze                                                                            Thermofischer Scientific                                                                                                   
Eppendorf Motion 5070 Pipetting Robot                                Eppendorf Motion 5070 
Filters (0.22 uM  and 0.45 uM)                                               Merck Millipore 
Freezing Container                                                                  Thermo Fischer  
Hemocytometer                                                                       Neubauer Improved, Isolab 
Ice Machine                                                                             AF20, Scotsman Inc. 
Incubator                                                                                 BE300, Memmert 
Laminar Flow                                                                          HeraSafe HS15, Heraeus, 
Liquid Nitrogen Tank                                                              Taylor-Wharton, 300RS   
Magnetic Strirrer                                                                     SB162, Stuart               
Microliter Pipettes                                                                   Eppendorf 
Microscope                                                                              CK40, Olympus 
pH Meter                                                                                  Mettler Toledo 
Refrigerator                                                                              Bosch 
                                                                                                 Arcelik 
 
SpectroFluorometer                                                                 Gemini SoftmaxPro 
Vortex                                                                                      VWR   
Water Bath                                                                               New Brunswick               
 
